UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJF) gapped down before the market opened on Monday . The stock had previously closed at $269.84, but opened at $255.52. UCB shares last traded at $255.52, with a volume of 525 shares trading hands.

Analysts Set New Price Targets

UCBJF has been the subject of several research analyst reports. Jefferies Financial Group raised UCB to a “hold” rating in a report on Monday, August 3rd. Piper Sandler reissued a “neutral” rating on shares of UCB in a research report on Wednesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, UCB has an average rating of “Moderate Buy”.

UCB Trading Down 1.2%

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The stock has a fifty day moving average of $290.62 and a 200 day moving average of $298.55.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.